A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis

Trial Profile

A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Upadacitinib (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT-EARLY
  • Sponsors AbbVie
  • Most Recent Events

    • 06 Oct 2017 Planned End Date changed from 9 Aug 2020 to 28 Mar 2021.
    • 06 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 15 Aug 2017 Planned End Date changed from 27 Mar 2021 to 9 Aug 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top